Vol 8, No 2 (2022)
Case report
Published online: 2022-06-23
New-onset psoriasis after rituximab for the treatment of granulomatosis with polyangiitis: A case report and review of the literature
12
, 1, , ,
, 1, , ,
DOI: 10.5603/RF.2022.0011
Rheumatology Forum 2022;8(2):91-93.
Abstract
Psoriasis is a chronic, immune-mediated, inflammatory condition seen frequently in clinical practice. Psoriasis may occur during different biologic therapies; however, this subject is still investigated. This case presents a 48-year-old female patient with granulomatosis with polyangiitis (GPA) treated with rituximab that developed drugrelated psoriasis. The pathogenetic mechanisms that may underlie such relationships are not yet understood.
Keywords: drug-induced-psoriasisrituximabpsoriasisgranulomatosis with polyangiitisbiological treatmentparadoxical effect
References
- Balak DMw, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckl). 2017; 7: 87–94.
- Karamanakos A, Vergou T, Panopoulos S, et al. Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy. Eur J Dermatol. 2021; 31(3): 307–317.
- Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016; 2(2): e000239.
- Bruzzese V, De Francesco V, Hassan C, et al. New onset or worsening of psoriasis following biologic therapy: A case series. Int J Immunopathol Pharmacol. 2017; 30(1): 70–72.
- Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008; 59(7): 996–1001.
- Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010; 40(3): 233–240.
- Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007; 56(8): 2715–2718.
- Markatseli TE, Kaltsonoudis ES, Voulgari PV, et al. Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. ClinExpRheumatol. 2009; 27(6): 996–8.
- Guidelli GM, Fioravanti A, Rubegni P, et al. Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature. Rheumatol Int. 2013; 33(11): 2927–2930.
- Toussirot É. New onset of psoriasis in a patient with rheumatoid arthritis treated with rituximab. J Rheumatol. 2013; 40(7): 1230–1231.
- Fiorillo L, Wang C, Hemmati I. Rituximab induced psoriasis in an infant. Pediatr Dermatol. 2014; 31(6): e149–e151.
- Mok MM, Yeung CK, Chan DT, et al. New onset psoriasis after rituximab for treatment of idiopathic membranous nephropathy. Nephrology (Carlton). 2014; 19(1): 60.
- Venables ZC, Swart SS, Soon CS. Palmoplantar pustulosis secondary to rituximab: a case report and literature review. Clin Exp Dermatol. 2015; 40(4): 451–452.
- Kim DW, Park SK, Woo SH, et al. New-onset psoriasis induced by rituximab therapy for non-Hodgkin lymphoma in a child. Eur J Dermatol. 2016; 26(2): 190–191.
- Aussy A, Girszyn N, Vandhuick T, et al. [Psoriatic arthritis during rituximab treatment of granulomatosis with polyangiitis: a new paradoxical side effect?]. Rev Med Interne. 2015; 36(7): 491–494.
- Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007; 56(8): 2715–2718.
